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Background: The purpose of this study was to assess the short- and long-term outcomes of HIV-infected patients
admitted to intensive care units (ICU) according to immunovirological status at admission and highly active
antiretroviral therapy (HAART) use in ICU.
Methods: Retrospective study of 98 HIV-infected patients hospitalized between 1997 and 2008 in two medical ICU
in Montpellier, France. The primary outcome was mortality in ICU. The secondary end point was probability of
survival in the year following ICU admission.
Results: Eighty-two (83.6%) admissions in ICU were related to HIV infection and 45% of patients had received
HAART before admission. Sixty-two patients (63.3%) were discharged from ICU, and 34 (34.7%) were alive at 1 year.
Plasma HIV RNA viral load (VL) and CD4+ cell count separately were not associated with outcome. Independent
predictors of ICU mortality were the use of vasopressive agents (odds ratio (OR), 3.779; 95% confidence interval (CI),
1.11–12.861; p= 0.0334) and SAPS II score (OR, 1.04; 95% CI, 1.003-1.077; p= 0.0319), whereas introducing or
continuing HAART in ICU was protective (OR, 0.278; 95% CI, 0.082-0.939; p= 0.0393). Factors independently
associated with 1-year mortality were immunovirological status with high VL (>3 log10/ml) and low CD4 (<200/
mm3; hazard ratio (HR), 5.19; 95% CI, 1.328-20.279; p= 0.0179) or low VL (<3 log10/ml) and low CD4 (HR, 4.714; 95%
CI, 1.178-18.867; p= 0.0284) vs. high CD4 and low VL, coinfection with C hepatitis virus (HR, 3.268; 95% CI, 1.29-8.278;
p= 0.0125), the use of vasopressive agents (HR, 3.68; 95% CI, 1.394-9.716; p= 0.0085), and SAPS II score (HR, 1.09;
95% CI, 1.057-1.124; p <0.0001). Introducing HAART in a patient with no HAART at admission was associated with a
better long-term outcome (HR, 0.166; 95% CI, 0.043-0.642; p= 0.0093).
Conclusions: In a population of HIV-infected patients admitted to ICU, short- and long-term outcomes are related
to acute illness severity and immunovirological status at admission. Complementary studies are necessary to
identify HIV-infected patients who benefit from HAART use in ICU according to immunovirological status and the
reasons of ICU admission.
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Since the highly active antiretroviral therapy (HAART)
era, mortality of HIV-infected patients in intensive care
units (ICU) has decreased from nearly 90% to 20% [1-9],
and reasons for admission of HIV-infected patients in
ICU have evolved from AIDS to non-AIDS classifying
complications [9,10].
Retrospective cohort studies have shown that prognos-
tic factors of mortality in HIV-infected patients admitted
to ICU were acute illness severity, poor functional status,
low albumin rate, and respiratory failure requiring
mechanical ventilation [2,8,11-14]. No specific HIV char-
acteristics (CD4 cell count value, plasma HIV RNA load,
HIV-related diagnosis, or management of antiretroviral
therapy) were clearly identified as predictors of ICU
mortality [6,8-13,15-21], except in one study where the
majority of ICU patients had an AIDS-defining illnesses,
in which very low CD4 T-cell count (<50 cells/mm3)
was found to be associated with ICU mortality [17]. We
believe that to consider CD4 value and HIV viral load
values separately in an HIV-infected population admit-
ted to ICU is not sufficient to assess the prognosis
properly.
In the non-ICU HIV-infected population, long-term
survival is closely related to both sustained HIV-
undetectable viral load under HAART and immune re-
constitution [22-24]. In the HIV-infected patients in
ICU, four retrospective studies analyzed the impact of
HAART and showed discordant results [8,9,17,21].
Moreover, management of HAART in ICU often is chal-
lenging because of potential toxicities and drug-to-drug
interactions.
The objective of this study was to analyze the impact
of immunovirological status and HAART use on short-
and long-term outcomes in HIV-infected patients admit-
ted to ICU.
Methods
Patients
This study was conducted retrospectively in two medical
ICUs, in a 2,300-bed University Hospital in France. All
HIV-infected patients admitted between January 1, 1997
and December 31, 2008 were included. Due to the geo-
graphic proximity of the Infectious Diseases Department
and the constant collaboration of the clinicians, policies
of admission of HIV-infected patient in ICU did not
change during this period. Clinical admission criteria of
HIV-infected patients to ICU did not take into account
HIV status.
When a patient was admitted more than once, only
the first admission was analyzed. HIV status was either
known before admission or discovered during ICU care.
Eligible patients were screened by an independent query
of the entire ICU database by the investigators and by across-computerized search from the Medical Informa-
tion Department for admission in ICU and any follow-
up in the Infectious Diseases Department or the Retro-
virology Laboratory Department. All ICU and Infectious
Diseases Department medical charts were reviewed by
an infectious diseases specialist (DM).
The study design was a retrospective review of patient
records in accordance with French law and did not re-
quire institutional ethics committee approval. Due to the
retrospective design of the study, we did not obtain
informed consent from the included patients. Neverthe-
less, all data collected retrospectively were anonymized
in a standardized case-report form and in the database.
Definitions
AIDS-defining illnesses before ICU admission were clas-
sified according to the latest statement of the Centers
for Disease Control and Prevention (CDC). HAART was
defined as a combination of three or more antiretroviral
drugs belonging to at least two classes among the fol-
lowing: protease inhibitors (PIs), nucleoside reverse tran-
scriptase inhibitors (NRTIs), and nonnucleoside reverse
transcriptase inhibitors (NNRTIs). Patients were consid-
ered as receiving HAART if it was introduced in the pre-
vious 30 days or more to admission.
Data collection and end points
The data were entered into an anonymous customized
database (Access 2003; Microsoft) and were subjected
to electronic validation rules. Demographic characteris-
tics, comorbidities, biological data (albumin, lactic acid,
thrombin time in the first 24 h) and details of life-
sustaining treatments used in the ICU (mechanical
ventilation, use of vasoactive drugs, renal replacement
therapy and durations) were recorded. The SAPS II
(Simplified Acute Physiology Score) and APACHE II
(Acute Physiology and Chronic Health Evaluation)
scores were calculated for each patient within the first
24 h of the ICU stay.
The primary outcome was mortality in ICU. The sec-
ondary end point was probability of survival in the year
following ICU admission. We looked for prognosis fac-
tors of short- and long-term mortality regarding popula-
tion, ICU disease, and HIV-related characteristics:
HAART use before ICU admission, plasma HIV RNA,
CD4 count, and HAART introduction or pursuance
in ICU.
Plasma HIV RNA and CD4 lymphocyte count mea-
sured during the 3 months before or the first week of
admission in ICU were used to define four groups:
– Patients with no or mild immune deficiency (CD4
lymphocyte cell count ≥200/mm3). Subgroups were
defined on their plasma HIV RNA viral load (VL)
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high + VLhigh]
and [CD4high + VLlow].
– Patients with severe immune deficiency (CD4
lymphocyte cell count <200/mm3) Subgroups were
defined in the same manner: [CD4low + VLhigh] and
[CD4low + VLlow].
The CD4 level threshold of 200/mm3 was chosen, be-
cause it is predictive of a high risk for opportunistic
infections and corresponds to the threshold at which an
anti-Pneumocystis and toxoplasmosis prophylaxis is pre-
scribed according to different national recommendations
[25]. The plasma HIV RNA VL threshold of 3 logs was
arbitrarily chosen to distinguish virological failure from
punctual replication under HAART (i.e., “Virologic blip”:
after virologic suppression, an isolated detectable HIV
RNA at low level that is followed by a return to virologic
suppression [26]).
Statistical analysis
Categorical variables are presented as frequencies with
percentages, and continuous variables are presented
as means and standard deviation (SD). Patients’ char-
acteristics were compared between the groups by
using the chi-square test, Fisher’s exact test, analysis
of variance, or Kruskal-Wallis test, when appropriate.
Logistic regression analysis was performed to identify
predictive factors for ICU mortality and Cox propor-
tional hazard models to identify predictive factors for
1-year mortality after admission in ICU. In both
methods, we first calculated crude odds ratio (OR)
and hazard ratio (HR) with their 95% confidenceFigure 1 Flow diagram of human immunodeficiency virus (HIV)-infect
the Montpellier Hospital from 1997 to 2008.intervals (CI) and then adjusted them with multivari-
ate models using a backward selection process with
p <0.1 used as the cutoff for retention in the mod-
els. To avoid collinearity, only one severity scoring
system was entered in multivariate models; SAPSII
were chosen because the models better fits the data.
The times to death during the first year after admis-
sion in ICU were compared between immunovirolo-
gical statuses using the log-rank test and illustrated by
Kaplan-Meier survival curves. Statistical analyses were
performed at the conventional two-tailed α level of
0.05 using SAS version 9.1 (SAS Institute, Cary, NC).
P <0.05 was considered significant.
Results and discussion
Results
Demographic and clinical characteristics of patients
Ninety-nine patients, corresponding to 104 ICU admis-
sions, were screened. One medical chart was missing,
and the patient was excluded from analysis. Three
patients had two ICU admissions, and one patient had
three admissions during the 11-year study period, result-
ing in 98 admissions of 98 HIV-infected patients ana-
lyzed (Figure 1).
The majority of the ICU cohort consisted of men
(70.4%). The mean age was 43.1 years, and HIV diagno-
sis was made more than 5 years before ICU admission
for 67 (68.4%) patients and less than 6 months for 17
patients (17.3%). Demographic and clinical characteris-
tics are presented in Table 1. Respiratory and neuro-
logical failures were the most common reasons for ICU
admission: 39% and 26% respectively. Sixty-threeed patients enrolled in the study at Medical Intensive Units of
Table 1 General characteristics of the 98 HIV-infected patients admitted to the ICU
Variable (n,%) Total Survived the ICU Died in the ICU p value
(n = 98) (n = 62) (n = 36)
Age, yr (mean± SD) 43.1 ± 10.7 43.2 ± 10.6 42.9 ± 10.9 0.815
Males 69 (70.4) 44 (71) 25 (69.4) 0.873
Comorbidities
Diabetes 10 (10.2) 8 (12.9) 2 (5.6) 0.316
HBs Ag-positive 14 (14.3) 8 (12.9) 6 (16.7) 0.607
Anti-hepatitis C virus positive 30 (30.6) 16 (25.8) 14 (38.9) 0.175
Alcohol abuse 29 (29.9) 18 (29.0) 11 (31.4) 0.804
Smoking 30 (30.9) 23 (37.1) 11 (31.4) 0.08
Main reason for ICU admission
Acute respiratory failure 38 (38.8) 24 (38.7) 14 (38.9) 0.888
Sepsis 11 (11.2) 6 (9.7) 5 (13.9) 0.57
Severe neurologic disorders 25 (25.5) 15 (24.9) 10 (27.8) 0.542
Miscellaneous 24 (24.4) 17 (27.4) 7 (19.4) -
Type of diagnosis at ICU admission
Opportunistic infection 25 (25.5) 16 (25.3) 9 (25.7)
Severe bacterial infection 36 (36.7) 22 (34.9) 14 (40)
Related to HIV HAART-induced complications 6 (6.1) 5 (7.9) 1 (2.8) 0.975
Non infectious disease related to HIV 15 (15.3) 7 (11.1) 8 (22.8)
Total 82 (83) 50 (79.3) 32 (91.4)
Unrelated to HIV 16 (16.3) 13 (20.7) 3 (8.6) 0.169
Details of opportunistic infection at the admission
Pneumocystis jirovecii pneumonia 11 (11.2) 6 (9.7) 5 (13.9)
Tuberculosis 1 (1) 0 1 (2.8)
Cerebral toxoplasmosis 6 (6.1) 5 (8.1) 1 (2.8) -
Cryptococcosis 3 (3.1) 2 (3.2) 1 (2.8)
Others 4 (4) 3 (4.8) 2 (5.6)
No opportunistic infection 73 (74.5) 46 (74.2) 27 (75) 0.621
Life-supporting procedures in ICU
Mechanical ventilation during the 24 first hours 59 (60.2) 28 (45.2) 31 (86.1) <0.001
Duration of mechanical ventilation, days (mean± SD) 9.59 ± 17.0 7.61 ± 15.4 13 ± 19.4 0.003
Renal replacement therapy 15 (15.3) 7 (11.3) 8 (22.2) 0.147
Duration of renal replacement therapy, days (mean± SD) 1.7 ± 6.4 1.3 ± 5.3 2.3 ± 8.1 0.37
Vasopressors 51 (52) 21 (33.9) 30 (83.3) <0.001
Duration of vasopressors, days (mean± SD) 3.8 ± 6.6 2.6 ± 4.5 5.9 ± 8.8 <0.001
Length of stay in ICU, days (mean± SD) 14 ± 17.5 13.4 ± 16.1 15.0 ± 19.9 0.431
Severity score (at 24 h)
SAPS II (mean± SD) 53.8 ± 20.7 46.5 ± 13.5 66.2 ± 24.9 <0.001
Biological data at admission
Albumin, g/L (mean± SD) 31.1 ± 14.2 32.8 ± 14.8 27.6 ± 12.4 0.125
Lactic acid, mmol/l (mean± SD) 2.9 ± 2.9 2.1 ± 1.9 4.4 ± 3.9 <.001
Thrombin time,% (mean± SD) 68.4 ± 22.9 72.5 ± 22 61.6 ± 23 0.034
ICU, intensive care unit; SD, standard deviation; SAPS, Simplified Acute Physiology Score; HBs Ag, hepatitis B virus surface antigen; HAART, highly active
antiretroviral therapy.
*p is significant.
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(52%) vasoactive drugs, and 15 (15.3%) renal replace-
ment therapy. Patients had a mean SAPS II score at 53.8
and a mean APACHE II score of 17.5, a mean serum al-
bumin of 31.1 g/L, and a mean serum lactic acid level of
2.9 mmol/l. The mean length of ICU stay was 14 days.Table 2 Demographic and baseline clinical characteristics of H
according to immunovirological statuses
Patie
Total n = 7
CD4
n=98 VLhig
Variable (n,%) n
Males 69 (70.4) 8 (5
Age, yr (mean± SD) 43.1 (10.7) 42.2
Time since HIV diagnosis
Less than 6 months 17 (17.3) 1 (7
Intermediate 14 (14.3) 4 (2
More than 5 years 67 (68.4) 9 (6
HIV diagnosis in ICU 8 (8.2) 0 (0
Comorbidities
HbsAg-positive. 14 (14.3) 3 (2
Anti-hepatitis C virus positive 30 (30.6) 10 (7
HbsAg+ antihepatitis C virus positive 7 (7.1) 3 (2
Alcohol abuse 29 (30) 8 (5
Tobacco 30 (31) 8 (5
Past medical history of cancer 13 (12.6) 0 (0
Main reasons for ICU admission
Acute respiratory failure 38 (38.8) 8 (5
Sepsis 11 (11.2) 1 (7
Severe neurologic disorders 25 (25.5) 2 (1
Miscellaneous 24 (24.5) 3 (2
Opportunistic infections
No opportunistic infection 73 14 (1
Pneumocystis jirovecii pneumonia 11 (11.2) 0 (0
Tuberculosis 1 (1) 0 (0
Toxoplasmosis 6 (6.1) 0 (0
Cryptococcosis 3 (3) 0 (0
Reactivation of cytomegalovirus (antigenemia positive) 15 (15.3) 0 (0
ICU data
SAPS II score (median) 49.5 52
APACHE II score (median) 17.5 16.5
Albumin, g/dL (median) 26.1 32.1
Mechanical ventilation in the first day 59 (60.2) 10 (7
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute P
virus; HCV, hepatitis C virus; HbsAg, hepatitis B virus surface antigen; ICU, intensive
cell/mm3; VL, viral load; VLhigh, ≥103 copies/ml; VLlow, <103 copies/ml; HAART, highl
*p is significant.HIV characteristics are presented in Tables 1 and 2.
Eighty-two (83.6%) admissions were related to HIV in-
fection: 25 admissions (25.5%) were due to an AIDS-
associated illness (11 Pneumocystis pneumonia, 6 cere-
bral toxoplasmosis, 1 tuberculosis, 3 cryptococcosis, 2
non-tuberculosis mycobacterium infections, and 2 severeIV-infected patients admitted to the ICU, stratified
nts with complete immunovirological status available
6
high CD4low CD4low CD4high p value
h VLhigh VLlow VLlow
= 14 n = 40 n= 10 n= 12
7.1) 28 (70) 8 (80) 10 (83.3) 0.496
(8.5) 40.1 (8.7) 46.8 (16.7) 54.7 (10.5) <0.001
.1) 8 (20) 1 (10) 0 (0)
8.6) 6 (15) 2 (20) 2 (16.7) 0.62
4.3) 26 (65) 7 (70) 10 (83.3)
) 6 (15) 0 (0) 0 (0) 0.217
1.4) 6 (15) 0 (0) 1 (8.3) 0.532
1.4) 7 (17.5) 4 (40) 2 (16.7) 0.001
1.4) 2 (5) 0 (0) 0 (0) 0.117
7.1) 13 (32.5) 2 (20) 2 (16.7) 0.137
7.1) 15 (37.5) 1 (10) 3 (25) 0.099
) 3 (7.5) 4 (40) 2 (16.7) 0.016
7.1) 16 (40) 2 (20) 3 (25)
.1) 3 (7.5) 1 (10) 2 (16.7) 0.749
4.3) 11 (27.5) 4 (40) 3 (25)
1.5) 10 (25) 3 (30) 6 (33.3)
00) 25 (62.5) 10 (100) 11 (91.7) 0.002
) 5 (12.5) 0 (0) 1 (8.3)
) 1 (1) 0 (0) 0 (0) -
) 4 (10) 0 (0) 0 (0)
) 2 (5) 0 (0) 0 (0)
) 10 (25) 0 (0) 1 (8.3) 0.054
48.5 56 49.5 0.522
18 20 14.5 0.509
28.8 30.7 42.1 0.169
1.4) 19 (47.5) 8 (80) 8 (66.7) 0.176
hysiology Score; ART, antiretroviral therapy; HIV, human immunodeficiency
care unit; CD4, lymphocyte T CD4(+); CD4high, ≥200 cell/mm3; CD4low, <200
y active antiretroviral therapy.
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infectious-complications of HIV infection (5 hemolytic
and uremic syndromes, 2 HIV-cardiomyopathy decom-
pensations, 2 lymphomas, 2 Castleman diseases, and 4
glomerulonephritis); 6 complications induced by specific
treatments: 1 hepatitis related to antituberculous, 1
methemoglobinemia with disulone, 1 severe thrombope-
nia due to cotrimoxazole, and 3 complications related to
HAART (1 Lyell disease due to nevirapine, 1 tubulopa-
thy due to tenofovir, and 1 pancreatitis related to di-
danosine), and 36 patients (36.7%) were admitted to ICU
for severe bacterial infections. Sixteen patients (16.3%)
had an HIV-unrelated event (severe asthma, brain
hemorrhage, medullar ischemia, ischemic heart failure,
severe metabolic disorders). Overall, 44 of 98 patients
(45%) received HAART at the time of ICU admission.
HAART was interrupted for more than 72 h during ICU
stay in 24 patients for nonspecified reasons. Nine
patients received HAART for the first time in ICU. Eight
patients (8%) had their HIV-infection discovered after
ICU admission.
Complete immunovirological statuses were determined
in 76 patients (77.6%): 4 patients had no plasma HIV
RNA and CD4 count, 1 had plasma HIV RNA but no
CD4 cell count, and 17 had a CD4 cell count but no
plasma HIV RNA. Clinical characteristics of these
patients are presented in Table 3. Patients were older in
group [CD4low + VLlow] or [CD4high + VLlow] than inTable 3 Specific characteristics of the 98 HIV-infected patient
Variables (%) Total
(n = 98)
HAART
No past history of HAART 24 (24
No HAART at the admission + no introduction in ICU 45 (45
No HAART at the admission + introduction in ICU 9 (9.2
HAART active at the admission and pursued 20 (20
HAART active at the admission and stopped 24 (24
Introducing or pursuing HAART in ICU 29 (29
Immunovirological data
Mean± SD CD4 (/mm3) } 173.5 ±
Mean± SD HIV RNA VL (103 copies/ml)} 274. 8 ±
CD4high (≥200/mm3) 30 (32
CD4low (<200/mm3) 63 (67
Combined CD4high + VLhigh 14 (18
subgroups CD4high + VL low 12 (15
CD4low + VLhigh 40 (52
CD4low + VLlow 10 (13
}93 patients; }77 patients.
ICU, intensive care unit; CD4, lymphocyte T CD4(+); CD4high, ≥200 cell/mm3; CD4low
HAART, highly active antiretroviral therapy.
*p is significant.group [CD4high + VLhigh] and in group [CD4low +
VLhigh]. Coinfection with hepatitis C virus was present in
71% of patients in group [CD4high+VLhigh] versus <40%
in the other groups (p= 0.001). In group [CD4low +
VLlow], all patients were treated with HAART for a long
time and viral load was <3 log10/ml for at least 1 year
before ICU admission. None of these patients had op-
portunistic infection at admission in ICU, and most of
them were hospitalized for various reasons, such as sui-
cide, gastrointestinal hemorrhage associated with end-
stage liver cirrhosis, septic shock after chemotherapy for
non-classifying-AIDS cancers, malignant hypercalcemia,
or acute lung injury. In this group, five patients left ICU,
but the only patient discharged alive from the hospital
died 6 months later.
In-ICU mortality and 1-year mortality
Thirty-six patients (36.7%) died in the ICU and 12
patients (12.2%) died in the hospital after ICU discharge
(Figure 1). From 1997 to 2008, ICU mortality decreased,
whereas severity score remained constant and patients
were older, but those trends were not significant
(Table 4). In univariate analysis, factors significantly
associated with ICU mortality were the use of vasopres-
sive agents or mechanical ventilation, the arterial lactic
acid value, and the severity scores (SAPS II or APACHE
II) at admission. In our study, neither CD4 T-cell count
(even for patient with very low cell count as <50/mm3)s
Survived the ICU Died in the ICU p value
(n =62) (n =36)
.5) 16 (25.8) 8 (22.2) 0.669
.9) 28 (45.2) 17 (47.2)
) 7 (11.3) 2 (5.6) 0.106
.4) 16 (25.8) 4 (11.1)
.5) 11 (17.7) 13 (36.1)
.6) 23 (37.1) 6 (16.7) 0.032
192 176.3 ± 197.1 168.7 ± 185.8 0.701}
664.9 282.6 ± 709.5 261.1 ± 591 0.975
.3) 20 (33.9) 10 (29.4) 0.656
.7) 39 (66.1) 24 (70.6)
.4) 9 (18.4) 5 (18.5)
.8) 10 (20.4) 2 (7.4) 0.429
.6) 25 (51) 15 (55.6)
.2) 5 (10.2) 5 (18.6)
, <200 cell/mm3; VL, viral load; VLhigh, ≥1,000 copy/ml; VLlow, <1,000 copy/ml;
Table 4 Evolution of ICU mortality, age, and SAPS II score of HIV-infected patients admitted to the ICU
Period All period 1997–2000 2001–2004 2005–2008 p value
n= 98 n=29 n=37 n=32
Died in ICU (n,%) 36 (36.7) 13 (44.8) 13 (35.1) 10 (31.2) 0.529
Died before hospital discharge (n,%) 47 (52.8) 13 (44.8) 20 (54.0) 14 (43.7) 0.832
Died at one year* (%) 55 50.4 59.6 52.7 0.843
Age (means, SD) 42.8 ± 10.6 36.1 ± 6.1 44.6 ± 10.1 47.6 ± 11.6 <0.001
SAPS II (means, SD) 53.2 ± 20.3 52.9 ± 25.7 51.7 ± 15.0 56.9 ± 21.5 0.406
ICU, intensive care unit; SD, standard deviation; SAPS, Simplified Acute Physiology Score.
*Percentage extrapolated from survival curves of Kaplan-Meier and compared using a log-rank test.
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admission, reason for admission, and immunovirological
status were significantly associated with ICU mortality.
Introducing or continuing HAART in ICU was signifi-
cantly associated with a better outcome (Table 3).
After multivariate logistic regression analysis including
the SAPS II score, the only independent predictors of
ICU mortality were the use of vasopressive agents (OR,
3.78; 95% CI, 1.11-12.86, p= 0.03) and the SAPS II score
(OR, 1.04; 95% CI, 1.00-1.08; p= 0.03), whereas introdu-
cing or continuing HAART in ICU was protective (OR,
0.28; 95% CI, 0.08-0.94; p= 0.04; Table 5).
Eight of the 50 patients who were discharged from
hospital were lost to follow-up. At 1 year after ICU ad-
mission, 34 patients (34.7%) were alive (Figure 1). With
univariate analysis, 1-year mortality was significantly
higher for patients classified in the group [CD4low +
VLlow] compared with all other groups (Table 5;
Figure 2). Introducing or continuing HAART in ICU
was not significantly associated with a better outcome.
Using Cox proportional hazard models, including the
SAPS II, the factors independently associated with 1-
year mortality were: belonging to the group [CD4low +
VLhigh] vs. [CD4high + VLlow] (HR, 5.19; 95% CI, 1.33-
20.28; p= 0.02) and to the group [CD4low+VLlow] vs.
[CD4 high + VLlow] (HR, 4.71; 95% CI, 1.18-18.87;
p= 0.03), coinfection with hepatitis C virus (HR, 3.27;
95% CI, 1.29-8.28; p= 0.01), the use of vasopressive
agents (HR, 3.68; 95% CI, 1.39-9.72; p ≤0.01), and the
SAPS II score (HR, 1.09; 95% CI, 1.057-1.124; p ≤0.0001;
Table 5). Introducing HAART in a patient with no
HAART at admission was associated with a better out-
come (HR, 0.17; 95% CI, 0.04-0.64; p ≤0.01).
Discussion
In this study, we observed a high rate of mortality in
ICU, a majority of admissions not primarily related to
opportunistic infections and only a few discoveries of
HIV infection after ICU admission. In this HIV-infected
population, we showed that mortality in ICU and during
the first year following admission were related to the
acute illness severity and immunovirological statuses atICU admission and that introduction or pursuit of
HAART seemed to be associated with a better outcome.
The 1-year mortality contrasted with the ICU mortality
(62.2% and 36.7% respectively), suggesting that the long-
term survival of critically ill HIV-infected patients was
still poor. Our in-ICU mortality was similar to other
centers in industrialized countries [12,16,27,28], but our
1-year survival rate was lower compared with the
few studies reporting long-term outcomes, in which
antiretroviral-naïve subjects were the vast majority
[15,17]. This last point can be explained by the fact
that the HIV-infected subjects in our study had a
long history of HIV infection and treatment and that
morbid outcomes after ICU discharge were independ-
ent of immune restoration under HAART (i.e., non-
AIDs defining cancers, decompensated cirrhosis).
As in several other studies, use of vasopressive agents,
mechanical ventilation, and severity scores at the admis-
sion were the main prognostic factors of ICU mortality
[9,10,18,19,28].
HIV-infected patients admitted to ICU do not form a
homogenous population and should be considered
according to their immunovirological status. For ex-
ample, patients with HAART failure and deep immuno-
logical deficiency, patients with AIDS classifying diseases
but who never had antiretroviral therapy, or patients in
the early stage of the HIV infection with high CD4 cell
count will probably have very different outcomes. These
different situations are not entirely captured by analyz-
ing separately plasma HIV RNA viral load and CD4+ cell
count. In our study, death at 1 year after admission was
not directly related to a CD4+ cell count <200/mm3.
We thus decided to classify patients into four groups
according to viral load and CD4 counts at the admission
and showed that patients from the groups [CD4low +
VLlow] or [CD4low + VLhigh] had a very bad outcome at
1 year compared with the group [CD4high + VLlow]. The
group [CD4low + VLlow] contained patients with viral
replication suppressed by HAART but without immune
reconstitution and the group [CD4low + VLhigh] patients
with HAART failure, whereas the group [CD4high +
VLlow] corresponded to patients with a good response to
Table 5 Univariate and multivariate analysis of variables associated with in-ICU and 1-year mortality
Variables ICU mortality One-year mortality
Crude odds ratio Adjusted odds ratio Crude hazard ratio Adjusted hazard ratio
OR [95% CI] p OR [95% CI] p HR [95% CI] p HR [95% CI] p
HAART
No HAART at admission + no
introduction in ICU
1.00 [−] - - 1.00 [−] - 1.00 [−]
No HAART at admission +
introduction in ICU
0.471 [0.087-2.533] 0.380 - 0.807 [0.277-2.355] 0.695 0.166 [0.043-0.642] 0.009
HAART active at admission
and pursued
0.412 [0.118-1.438] 0.164 - 0.948 [0.446-2.014] 0.889 1.519 [0.519-4.444] 0.446
HAART active at the
admission and stopped
1.947 [0.713-5.312] 0.193 - 1.827 [0.963-3.466] 0.065 1.758 [0.633-4.887] 0.279
Introducing or pursuing
HAART in ICU
0.339 [0.123-0.937] 0.037 0.278 [0.082-0.939] 0.039 0.72 [0.39-1.33] 0.294 -
Immunovirological status
CD4 T-cell count <200 /mm3 1.332 [0.542-3.273] 0.532 - 1.348 [0.73-2.489] 0.34 -
HIV RNA load >1,000 copy/mL 1.153 [0.503-2.645]- 0.737 - 0.935 [0.541-1.616] 0.809 -
CD4high + VL low 1.00 [−] - - 1.00 [−] - 1.00 [−] -
Combination CD4high + VLhigh 2.778 [0.428-18.037] 0.857 - 2.736 [0.707-10.594] 0.145 2.344 [0.442-12.434] 0.317
CD4low + VLhigh 3.000 [0.578-15.583] 0.659 - 2.583 [0.77-8.670] 0.124 5.19 [1.328-20.279] 0.018
CD4low + VL low 5.000 [0.704-35.493] 0.208 - 7.411 [2.02-27.195] 0.002 4.714 [1.178-18.867] 0.028
Comorbidity
Hepatitis C virus infection 1.83 [0.760-4.406] 0.178 - 1.469 [0.829-2.603] 0.1879 3.268 [1.29-8.278] 0.012
In-ICU data
Use of vasoactive drugs 9.762 [3.512-27.132] <0.001 3.779 [1.11-12.861] 0.033 4.2 [2.257-7.815] <0.001 3.68 [1.394-9.716] 0.008
Mechanical ventilation 7.529 [2.585-21.923] <0.001 3.317 [0.955-11.521] 0.059 3.139 [1.64-6.007] <0.001 -
Albumin 0.97 [0.926-1.015] 0.19 - 0.968 [0.937-1.001] 0.058 -
Acid lactic in the first 24 h 1.326 [1.104-1.593] 0.002 - 1.205 [1.109-1.31] <0.001 -
SAPS II 1.06 [1.029-1.091] <0.001 1.04 [1.003-1.077] 0.032 1.065 [1.048-1.084] <0.001 1.09 [1.057-1.124] <0.001
ICU, intensive care unit; CD4, lymphocyte T CD4(+); CD4high, ≥200 cell/mm3; CD4low, <200 cell/mm3; VL, viral load; VLhigh, ≥103 copy/ml; VLlow, <103 copy/ml;
HAART, highly active antiretroviral therapy; OR, odds ratio; HR, hazard ratio; CI, confidence interval; SAPS, Simplified Acute Physiology Score; HBs Ag, hepatitis B
virus surface antigen.
*p is significant.
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RNA viral load and CD4+ cell count have never been
evaluated as prognostic factor in HIV-infected patients
admitted to ICU.
In the general HIV-infected population presenting an
opportunistic infection, early HAART resulted in less
AIDS progression/death with no increase in adverse
events or loss of virologic response compared to de-
ferred HAART [29]. Moreover, it is now recommended
to prescribe HAART in the majority of HIV-infected
patients even for high CD4 level [26]. Management of
antiretroviral therapy is a challenge in ICU, and introdu-
cing HAART in a patient with no HAART at admission
is a difficult decision. There are no pharmacologic and
pharmacokinetic data concerning antiretroviral therapy
in hemodynamically unstable patients. Drug-to-drug
interactions are expected with antiarrhythmics,anticonvulsants, antifungal, antibiotics, gastrointestinal
drugs, or sedative drugs, such as midazolam. Only AZT
can be used for intravenous administration, and pharma-
cokinetics of administration using nasogastric tubes for
others compounds are uncertain and could lead to poor
drug absorption and further development of resistance.
In our study, we showed that introducing or continuing
HAART in HIV-infected patients in ICU seems to be
protective in the short-term and introducing HAART in
a patient with no HAART at admission seems to be
associated with a better long-term outcome. One must
probably discriminate HIV-related situations in which
immune restoration is crucial for clinical response or to
prevent other complications (especially in case of long
period of ICU) from other situations.
Only four retrospective studies analyzed the impact of
HAART in ICU and showed discordant results. A study
Figure 2 Kaplan-Meier survival curves illustrating time to death during the first year after admission in ICU according to the immune-
virological status.
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General Hospital found that HAART use at ICU ad-
mission was not associated with a better hospital sur-
vival but was associated with predictors of better
outcome, such as higher serum albumin concentrations
[8]. The second study from São Paulo University Hos-
pital analyzed predictive factors of mortality for 278
HIV patients admitted to ICU; 193 of them (69.4%)
died before 6 months [17]. They demonstrated that
HAART use in ICU was negatively predictive of 6-
month mortality, especially if this therapy was intro-
duced during the first 4 days of admission in ICU.
However, contrasting with our and other studies,
80.6% of the ICU admissions were due to AIDS-
defining conditions, and all subjects had very low CD4
counts. The third study from Saint Louis hospital in
Paris [9] analyzed predictive factors of mortality for
284 HIV patients admitted to ICU and showed that
comorbidities and organ dysfunctions, but not HIV-
related variables, were associated with death. Among
the 233 (82%) patients with known HIV infection be-
fore ICU admission, 64% were on HAART but
HAART use at ICU admission was not associated with
ICU mortality.
The most recent study, from the University Medical
Center Utrecht in Netherlands [21], analyzed character-
istics from patients admitted to the ICU during the pre-HAART era (n = 47), and during the HAART period
(1996–2008, n = 80). The 1-year mortality in the HAART
era decreased to 51%. Predictors of short- and long-term
(1 year and 5 years) mortality in the HAART era were
older age, APACHE II score> 20, and the use of mech-
anical ventilation, but neither HIV-related factors nor
the use of HAART on ICU admission were significant.
Our study has several limitations. First, the design was
retrospective. All patients were managed in two different
ICU without standardized, written protocols, but all
patients had a follow-up in the same Infectious Diseases
Department and no data of ICU concern were missing.
Loss of follow-up is less than 10%, which is usual in this
pathology. During this period, we recorded only 104
admissions in this two medical ICU, but we have no data
about HIV-infected patients hospitalized in surgical ICU.
Second, the study period is very long (11 years), com-
prising progress in critical care practices during the past
decade: use of low tidal volumes for patients with re-
spiratory failure, adjuvant corticosteroids for certain
conditions, and early goal-directed therapy for sepsis.
Even if the admission policy of HIV-infected patients
remains constant in our centers, antiretroviral therapy
also has evolved and new combinations are supposed to
enhance efficiency with fewer adverse events. However,
number of admissions, age, and severity scores through-
out the different periods were not significantly different
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virological subgroup were too small to discriminate
patients who really benefited from HAART use in ICU.
Our results suggest that introduction of HAART is
beneficial in some patients in the ICU, but this protect-
ive effect may be simply an association rather than a
causative factor.
Conclusions
In our population of HIV-infected patients admitted to
ICU, the ICU and 1-year mortality are related to acute
illness severity and immunovirological status at admis-
sion. Complementary studies are necessary to identify
HIV-infected patients who benefit from HAART use in
ICU according to immunovirological status and the rea-
sons of ICU admission.
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